Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06190093 · ClinicalTrials.gov registry record · Phase 3
A 3-month Study to Assess the Safety and Effectiveness of ONS-5010 in Subjects With Neovascular Age-related Macular Degeneration (AMD)
A Phase 3 study, sponsored by Outlook Therapeutics.
- Completed
- Registry status
- Phase 3
- Development phase
- 400
- Enrollment target
NCT06190093 is a Phase 3 study that has completed, run by Outlook Therapeutics. The registered enrollment target is 400 participants.
The verdict
NCT06190093, a Phase 3 study, has completed, sponsored by Outlook Therapeutics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 400 participants
- Enrollment target
Study Summary
Multicenter, randomized, masked, controlled study of the safety and effectiveness of intravitreally administered ONS-5010.
Interventions
- BIOLOGICAL bevacizumab
- BIOLOGICAL ranibizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 400 participants |
| Start Date | 2024-01-24 |
| Est. Completion | 2024-12-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06190093
The ClinicalTrials.gov registry entry for NCT06190093 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 400 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Outlook Therapeutics, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which bevacizumab is the first listed.
NCT06190093 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06190093 about?
NCT06190093 is a clinical study titled "A 3-month Study to Assess the Safety and Effectiveness of ONS-5010 in Subjects With Neovascular Age-related Macular Degeneration (AMD)". Multicenter, randomized, masked, controlled study of the safety and effectiveness of intravitreally administered ONS-5010.
What is the current status of trial NCT06190093?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 400 participants. The study started on 2024-01-24. Estimated completion is 2024-12-05.
What interventions are being tested in trial NCT06190093?
The interventions under investigation include: bevacizumab (BIOLOGICAL), ranibizumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT06190093?
This trial is sponsored by Outlook Therapeutics, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.